AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
The global embolotherapy market is expected to grow from $3.16 billion in 2024 to $5.82 billion by 2033, driven by the increasing prevalence of cancer, vascular disorders, and trauma cases. Innovations in embolic agents and delivery devices have enhanced procedural accuracy and outcomes. Healthcare facilities are adopting next-gen embolotherapy technologies to address growing procedure volumes and improve patient outcomes. Cancer and vascular diseases are key drivers of the embolotherapy industry, with liver cancer cases expected to rise from 2022 to 2040. The market is segmented by product, application, end-use, and region, with key players including Penumbra, Inc. and others.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet